Omega-3 Index is Directly Associated with a Healthy Red Blood Cell Distribution Width

Michael I. McBurney[1-3], Nathan L. Tintle[1,4], and William S. Harris[1,5]

[1]Fatty Acid Research Institute, Sioux Falls, SD 57106, USA (MIM, NLT, WSH); [2]Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada (MIM), [3]Division of Biochemical and Molecular Biology, Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA 02111, USA (MIM); [4]Department of Population Health Nursing Science, College of Nursing, University of Illinois – Chicago, Chicago, IL 60612, USA(NLT); [5]Sanford School of Medicine, University of South Dakota, Sioux Falls, SD 57105, USA (WSH).

Authors' last names: McBurney, Tintle, Harris

Corresponding author: M.I. McBurney, Department of Human Health & Nutritional Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada. E-mail: mim@faresinst.com

Reprint requests: W.S. Harris, Fatty Acid Research Institute, Sioux Falls, SD 57106, USA. E-mail: wsh@faresinst.com

Sources of Support: This work was supported by the Fatty Acid Research Institute (FARI). FARI is a non-profit foundation bringing together nutrition scientists and biostatistical experts to accelerate discovery of the relationships between fatty acids, especially omega-3 fatty acids, and health. Pending application and approval, data described in the manuscript, code book, and analytic code will be made available upon request to the Fatty Acid Research Institute (https://www.faresinst.org/).

Abbreviations: BMI, body mass index; CRP, high-sensitivity C-reactive protein; CV, coefficient of variation; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; Hb, hemoglobin; MCV,

24 mean corpuscular volume; O3I, omega-3 index; RBC, red blood cells. RDW, red blood cell

25 distribution width; SD, standard deviation.

26

Summary

Low red blood cell (RBC) membrane content of EPA and DHA, i.e., the omega-3 index (O3I), and elevated RBC distribution width (RDW) are risk factors for all-cause mortality. O3I and RDW are related with membrane fluidity and deformability. Our objective was to determine if there is a relationship between O3I and RDW in healthy adults. Subjects without inflammation or anemia, and with values for O3I, RDW, high-sensitivity C-reactive protein (CRP), body mass index (BMI), age and sex were identified (n=25,485) from a clinical laboratory dataset of >45,000 individuals. RDW was inversely associated with O3I in both sexes before and after (both $p<0.00001$) adjusting models for sex, age, BMI and CRP. Stratification by sex revealed a sex-O3I interaction with the RDW-O3I slope ($p<0.00066$) being especially steep in females with O3I ≤5.6%. In healthy adults of both sexes, the data suggested that an O3I of >5.6% may help maintain normal RBC structural and functional integrity.

Keywords: hematology, red blood cells, omega-3 index, eicosapentaenoic acid, docosahexaenoic acid

1. Introduction

Mean red blood cell (RBC) corpuscular volume (MCV) and reticulocyte count were the principal metrics traditionally used to identify anemic disorders until the advent of automated blood cell analyzers that could routinely measure the types and distribution of blood cells. Among these metrics is the RBC distribution width (RDW) [1] which reflects RBC size heterogeneity. High RDW values are associated with decreased deformability [2] and RDW is used to diagnose sickle cell [3] and nutritional anemias (iron, folic acid and vitamin B12) [1,4,5]. In recent years, RDW has been found to be a predictor of multiple adverse health outcomes unrelated to anemia, including increased risk for death from cardiovascular disease [6–12], SARS-CoV-2 [13–15], sepsis [16,17], lung disease [18], and cancer [19,20].

Like all cell membranes, RBC membranes are a complex lipid bilayer [21]. Fatty acids esterified in phospholipids contribute to the structural integrity and function of cell membranes. In particular, the membrane content of omega-3 fatty acids, EPA and DHA, the sum of which is called the omega-3 index (O3I) [22], increases with omega-3 fatty acid intake [23,24] and affects cell deformability [25–28]. The O3I is a stable biomarker of long term EPA and DHA intake [24,29]. Since both a low O3I [30] and an elevated RDW [7,31,32] are known to be associated with risk for earlier all-cause mortality (**Supplemental Table 1**), the aim of this cross-sectional analysis was to determine if there was an inverse relationship between the O3I and RDW in healthy adults without evidence of inflammation or tissue injury. If there was, then the former may play a role in maintaining a healthy distribution of RBC sizes in adults. Furthermore, such a relationship could support the identification of a target or healthy O3I. By establishing a nutrient: structure-function relationship in healthy individuals, these data could

be used as the basis for establishing a Dietary Reference Intake (DRI) for the long-chain omega-3 fatty acids, i.e., EPA+DHA.

2. Patients and Methods

This was a cross-sectional analysis of data from blood samples submitted for testing to Health Diagnostic Laboratory, Inc (HDL, Inc., Richmond VA) as part of routine clinical assessment between 2011-2012. Data on RBC structural characteristics, i.e., MCV and RDW, along with hemoglobin (Hb), high-sensitivity C-reactive protein (CRP), arachidonic acid (AA), EPA, DHA, and O3I were extracted from 45,715 adults (≥18 years) without any linked patient identifiers except age, sex and BMI (**Supplemental Table 2**). Next, 598 individuals with extreme O3I values (i.e., <2.15 and >11.5%, the upper and lower 0.5 percentiles of the cohort), were excluded (n=45,257). Since inflammation affects erythropoiesis, modulates RBC life span, and increases RDW [33], 14,329 individuals with chronic inflammation (CRP >3mg/L) [34–38] were excluded. Similarly, anemia also increases RDW [1,39], and so individuals with MCV >100 fL and low Hb (Hb <13 g/dL for men and Hb <12 g/dL for women [40] were also excluded (**Figure 1**). This resulted in a final, analytical dataset of 25,485 individuals (49.7% female) without laboratory evidence of anemia or active infection, tissue injury, or inflammation (**Table 1**).

2.1 Laboratory methods

Blood samples were drawn after an overnight fast and shipped with cold packs to HDL, Inc. for analysis with a Beckman-Coulter DxH 800 hematology analyzer (Brea, CA, USA). Samples were prepared at each clinical site according to standardized instructions as previously described [41]. RDW is the SD of the RBC volume divided by the MCV multiplied by 100 [39].

88 For fatty acid analysis, RBCs were separated from plasma by centrifugation and analyzed using
89 gas chromatography as previously described [42]. The University of South Dakota Institutional
90 Review Board reviewed and approved the analysis of deidentified HLD, Inc. laboratory data
91 (IRB-21-147).

92 *2.2 Statistical methods*

93 Sample characteristics were summarized using standard statistical methods (e.g., means,
94 SDs, correlations) with t-tests or adjusted linear models used to compare characteristics of male
95 and female participants above and below O3I values that were ultimately identified as primary
96 cut points in the RDW-O3I curves (see below). Splines were fit using 3rd degree polynomials
97 with knots at each decile in R (version 3.6.2; splines package). Unadjusted models used a linear
98 model to predict RDW values by splines of O3I. Adjusted models accounted for sex, age, BMI
99 and CRP values in the linear models accounting for potential non-linear relationships using
100 splines.

101 In order to identify significant changes in the shape of the RDW-O3I relationship, we used a
102 "sliding O3I window" approach. The width of each window was three O3I percentage points
103 (e.g., 3% to 6%). By moving the window up by 0.1% increments and repeatedly testing for
104 significant differences between the mean RDW in the lower vs. the upper half of the window,
105 we sought to discover O3I cut points where the RDW-O3I relationship appeared to flatten.
106 These would be O3I values above which the "effect" of an increase in O3I on RDW had little
107 impact. We began with a window midpoint of O3I =2.6%, and we used adjusted linear models in
108 R to test for upper vs lower half differences. We identified the first window which did not have
109 a statistically significant difference in upper and lower mean RDW values. The midpoint of this

window was chosen as the O3I cut point to be used in further analysis. To evaluate the potential moderating effect of sex on the O3I relationship with RDW, MCV, Hb, CRP, BMI and age, we inserted an interaction term into the relevant, adjusted model. Pearson correlations were used to assess strength and direction of linear association between covariates and RDW. Statistical significance was set to 0.05 for all analyses and 95% confidence bands are provided where appropriate.

3. Results

The final dataset included 25,485 individuals (**Figure 1**) without acute inflammation or anemia. Mean BMI, O3I, MCV, Hb, and CRP values differed significantly between males and females in adjusted models (**Table 1**). RDW was significantly ($p<0.00001$) and inversely associated with O3I in unadjusted (**Figure 2A**) and adjusted models ($p<0.00001$) (**Figure 2B**). Independently, EPA and DHA had similar 'hockey stick' RDW-fatty acid relationships with the bases of the curves being ~3% and ~7.3%, respectively (**Supplemental Figure 2**). RDW was not significantly related with AA (**Supplemental Figure 2,** r=0.06). Pearson correlations (r) with RDW were r=0.21 (age), r=0.11 (CRP), r=0.14 (BMI), r=-0.25 (MCV), and r=-0.12 (Hb). The O3I cut point determined in the sliding window analysis, i.e. when the lower and upper half of an "O3I sliding window" yielded mean RDW values that did not significantly differ, was 5.6% (**Figure 2B**). That is, below an O3I of 5.6%, the curve was clearly steeper than it was above 5.6%. Because of significant sex differences in RDW and O3I in the adjusted model (**Table 1**), and because of the clear differences in the shapes of the RDW-O3I relationship between men and women **(Figure 2)**, we stratified by sex and by O3I (≤5.6% vs >5.6%) (**Table 2**). Within sex comparisons found significant differences between individuals with O3I ≤5.6% vs. >5.6% for all variables in the

adjusted model for females and males (**Table 2**). We observed a significant sex by O3I interaction in the adjusted model for RDW and BMI for both sexes with the difference in RDW below 5.6% being larger in females than males. Across all O3I concentrations, RDW continued to decrease with increasing O3I in females whereas there was a plateauing in males, and even a modest increase in RDW as O3I exceeded 8% (**Figure 3**).

4. Discussion and Conclusions

RBCs are by far the most common cell in the body (83%), and as such, they have recently been viewed as a separate organ deeply involved with homeostasis [43]. Their primary role is to transport oxygen and carbon dioxide, and to accomplish this RBCs must pass through capillaries whose diameter is half of their own [44]. Thus, RBCs must be highly flexible and able to withstand high-shear stress. Here, we report an inverse relationship between the percentage of omega-3 fatty acids in RBC membranes and the distribution of RBC sizes in a generally healthy (i.e., not anemic and without inflammation) cohort (**Figure 2**), as well as an interaction with sex (**Figure 3**). In both males and females, RDW was observed to be increasing with decreasing O3I below 5.6% (**Figure 2; Table 2**). The direction of the O3I-RDW relationship changed in males with O3I >~8% but the increase in RDW is unlikely to have clinical significance.

Changes in saturated and unsaturated fatty acid composition in cell membranes affect membrane fluidity [45–47] and deformability [28,48]. EPA and DHA have specific biophysical properties that affect the properties of membranes enriched in them [49]. Among these properties are fluidity, deformability, and susceptibility to aggregation of RBCs [26,28]. Increases in membrane DHA (a highly flexible molecule) influence the flexibility and structural

154 integrity, i.e. lipid-protein interactions, of RBC membranes [50]. Increasing EPA intake alone or
155 EPA+DHA together increases RBC membrane fluidity [48] and RBC deformability [25–27,51].
156 RBC deformability is affected by membrane lipid composition and lipid-protein interactions, and
157 reduced deformability is a characteristic of aged RBCs [52]. Since an elevated RDW is likewise
158 associated with decreased RBC membrane flexibility [2], one possible explanation for our
159 findings is that a reduced EPA+DHA content of RBC membranes is causing the elevation in RDW.
160 An elevated RDW can also be caused by disordered erythropoiesis and/or RBC clearance
161 [53]. A delay in clearance allows smaller RBCs to continue circulating, increasing the average
162 age (lifespan) of RBC, and contributes to increased RDW [2]. Oxidative stress is a characteristic
163 of aging, malnutrition, inflammation, and the pathogenesis of chronic disease [54]. Oxidative
164 stress changes cytoskeletal arrangement and contributes to lipid asymmetry, causing
165 erythrocytes lose flexibility and RDW to increase [55]. A systematic review and meta-analysis of
166 39 clinical trials (2,875 participants) found omega-3 supplementation improved antioxidant
167 stability by significantly increasing serum total antioxidant capacity and decreasing serum
168 glutathione peroxidase and malondialdehyde concentrations [56]. This represents another
169 means by which omega-3 fatty acids could improve the RDW.
170 Alternatively, there may be a connection between omega-3, inflammation and the RDW.
171 Inflammation marked by elevated CRP, interleukin-6, etc. can suppress RBC maturation in bone
172 marrow, and larger immature RBCs, i.e. reticulocytes, enter the circulation and increase the
173 RDW [16]. This relationship between RDW and inflammation may partially explain the
174 relationship of higher RDW with risk of cardiovascular disease and mortality
175 [10,11,14,30,32,57]. Similarly, lower omega-3 fatty acid levels are associated with a heightened

176 inflammatory state [58–60], and omega-3 supplementation lowers inflammatory mediators
177 [61]. Thus, a possible explanation of our findings may be that higher omega-3 fatty acid levels
178 (O3I >5.6%) lower inflammatory markers which thereby lowers the RDW. Because it has been
179 recommended that a DRI be established for EPA+DHA [62–65], the RDW-O3I analysis was
180 purposefully constrained to healthy individuals with an objective of establishing a nutrient
181 (EPA+DHA) structure-function (RDW) relationship. When the 14,239 individuals with
182 inflammation (CRP >3 mg/L) were also included in the adjusted and unadjusted models, a
183 similar inverse RDW-O3I relationship was determined (**Supplemental Figure 2**).

184 Because of its cross-sectional nature, we cannot draw causal inferences from these data.
185 However, there is evidence that raising RBC membrane omega-3 content can improve RDW. In
186 patients with sickle cell disease, RBC rheological disturbances, hemolysis, and abnormalities of
187 membrane fatty acids, have been ameliorated by omega-3 fatty acid treatment [66,67].
188 Supplementation with both EPA alone or EPA+DHA lowered RDW values in patients with
189 coronary heart disease [51,68] and with abdominal aortic aneurysm [69]. In the latter study,
190 supplementation increased O3I from ~4.5% to 8% and decreased RDW from 14.8% to 13.8%.
191 So, one of the mechanisms underlying the health benefits of EPA and DHA could be via an
192 improved RDW.

193 The primary strength of this study was its large sample size which enabled us to explore
194 RDW and O3I relationships in healthy individuals (males and females separately) free of
195 laboratory signs of anemia or inflammation, i.e., a population suitable for the establishment of
196 a DRI. The most obvious limitations of this study, besides its cross-sectional nature, was the lack
197 of information on confounding metabolic events, dietary behaviors, medications, other medical

198 conditions and/or physical activities that might have also been associated with O3I and with
199 RDW. Another potential limitation is that these data were drawn from a clinical laboratory
200 database, not a formal national survey, so the representativeness of these patients to healthy
201 US adults is not clear. However, previous studies in this specific cohort found that standard risk
202 biomarkers (cholesterol, glucose, etc.) generally reflected those of typical adults living in the
203 United States examined in Nutrition And Health Examination Surveys (NHANES) [70]. Also, O3I
204 values were similar to those from a representative US sample [71], and RDW, MCV, and Hb
205 were within normal ranges [7,72,73]. These considerations suggest this cohort was generally
206 representative of the US population. The mean serum EPA+DHA concentration for adults 20+
207 years from NHANES was 2% [71] which is equivalent to an O3I of about 4.8%. Hence, roughly
208 half of Americans have an O3I <5%, i.e., the range where higher RDW may be more common.
209 In conclusion, low O3I levels (≤5.6%) were associated with a potentially unhealthy
210 distribution of RBC cell sizes. This suggests a role for EPA+DHA in maintaining RBC structure in
211 healthy individuals. We propose that achieving an O3I >5.6% could help maintain a normal RBC
212 size distribution. Our finding complements evidence that a higher O3I is linearly and inversely
213 associated with risk for death from any cause [30], with values of >8% characterizing the lowest
214 risk population [74]. Numerous researchers have called for the establishment of Dietary
215 Reference Intake (DRI) for EPA+DHA [63–65]. To that end, our observations that maintaining an
216 RBC EPA+DHA percentage above 5.6% may help maintain a normal RDW, could provide the
217 scientific basis for a DRI.
218

Disclosures: M.I. McBurney serves on the Board of Directors of the American Society for Nutrition and has or has held consulting agreements in the past 3 years with Council for Responsible Nutrition; Church & Dwight; DSM Nutritional Products; International Life Sciences Institute, North America; McCormick; OmegaQuant Analytics; PepsiCo; and VitaMe Technologies. W.S. Harris holds an interest in OmegaQuant Analytics, a lab that offers omega-3 blood testing; and is a member of the RB Schiff Science and Innovation Advisory Board. N.L. Tintle has no conflicts to disclose.

Funding: This work was supported by the Fatty Acid Research Institute (FARI). FARI is a non-profit foundation bringing together nutrition scientists and biostatistical experts to accelerate discovery of the relationships between fatty acids, especially omega-3 fatty acids, and health.

CReditT authorship contribution statement: M.I. McBurney: Conceptualization & analytical design, Writing - original draft, Writing - review & editing. **W.S. Harris**: Conceptualization & analytical design, Funding - acquisition, Writing- review & editing. **N.L. Tintle**: Formal analysis, Writing - review & editing.

Acknowledgements: The authors wish to thank Dr. Patrick Moriarty, Department of Internal Medicine, Kansas University Medical Center, Kansas City, KS for the initial suggestion to explore the relationship between omega-3 status and RDW. We also are indebted to Steven Varvel, PhD for his help in acquiring and collating the dataset used in this study.

238 **References**

239 [1] J.D. Bessman, P.R. Gilmer, F.H. Gardner, Improved Classification of Anemias by MCV and
240 RDW, Am J Clin Pathol. 80 (1983) 322–326. https://doi.org/10.1093/ajcp/80.3.322.
241 [2] K.V. Patel, J.G. Mohanty, B. Kanapuru, C. Hesdorffer, W.B. Ershler, J.M. Rifkind, Association
242 of the Red Cell Distribution Width with Red Blood Cell Deformability, in: W.J. Welch, F.
243 Palm, D.F. Bruley, D.K. Harrison (Eds.), Oxygen Transport to Tissue XXXIV, Springer New
244 York, New York, NY, 2013: pp. 211–216. https://doi.org/10.1007/978-1-4614-4989-8_29.
245 [3] D.J. Schweiger, Red cell distribution width in sickle cell anemia, Am J Med Technol. 47
246 (1981) 231–233.
247 [4] R.O. Wallerstein, Laboratory Evaluation of Anemia, West J Medicine. 146 (1987) 443–451.
248 [5] W.G. Thompson, T. Meola, M. Lipkin, M.L. Freedman, Red Cell Distribution Width, Mean
249 Corpuscular Volume, and Transferrin Saturation in the Diagnosis of Iron Deficiency, JAMA
250 Intern. Med. 148 (1988) 2128–2130.
251 [6] M. Tonelli, F. Sacks, M. Arnold, L. Moye, B. Davis, M. Pfeffer, Relation between Red Blood
252 Cell Distribution Width and Cardiovascular Event Rate in People with Coronary Disease,
253 Circulation. 117 (2008) 163–168. https://doi.org/10.1161/CIRCULATIONAHA.107.727545.
254 [7] S.K. Zalawadiya, V. Veeranna, S.S. Panaich, L. Afonso, J.K. Ghali, Gender and Ethnic
255 Differences in Red Cell Distribution Width and Its Association With Mortality Among Low
256 Risk Healthy United State Adults, The American Journal of Cardiology. 109 (2012) 1664–
257 1670. https://doi.org/10.1016/j.amjcard.2012.01.396.
258 [8] B.F. Makhoul, A. Khourieh, M. Kaplan, F. Bahouth, D. Aronson, Z.S. Azzam, Relation
259 between changes in red cell distribution width and clinical outcomes in acute

260 decompensated heart failure, Int J Cardiol. 167 (2013) 1412–1416.
261 https://doi.org/10.1016/j.ijcard.2012.04.065.
262 [9] N. Li, H. Zhou, Q. Tang, Red Blood Cell Distribution Width: A Novel Predictive Indicator for
263 Cardiovascular and Cerebrovascular Diseases, Disease Markers. 2017 (2017) 1–23.
264 https://doi.org/10.1155/2017/7089493.
265 [10] N. Shah, M. Pahuja, S. Pant, A. Handa, V. Agarwal, N. Patel, R. Dusaj, Red cell distribution
266 width and risk of cardiovascular mortality: Insights from National Health and Nutrition
267 Examination Survey (NHANES)-III, Int. J. Cardiol. 232 (2017) 105–110.
268 https://doi.org/10.1016/j.ijcard.2017.01.045.
269 [11] S. Huang, Q. Zhou, N. Guo, Z. Zhang, L. Luo, Y. Luo, Z. Qin, L. Ge, Association between red
270 blood cell distribution width and in-hospital mortality in acute myocardial infarction,
271 Medicine. 100 (2021) e25404. https://doi.org/10.1097/MD.0000000000025404.
272 [12] D. Lazzeroni, L. Moderato, P.L. Marazzi, C. Pellegrino, E. Musiari, P. Castiglioni, U.
273 Camaiora, M. Bini, S. Geroldi, L. Brambilla, V. Brambilla, P. Coruzzi, Red blood cell
274 distribution width as a novel prognostic marker after myocardial revascularization or
275 cardiac valve surgery, Sci Rep. 11 (2021) 7889. https://doi.org/10.1038/s41598-021-
276 87075-4.
277 [13] B.H. Foy, J.C.T. Carlson, E. Reinertsen, R. Padros I. Valls, R. Pallares Lopez, E. Palanques-
278 Tost, C. Mow, M.B. Westover, A.D. Aguirre, J.M. Higgins, Association of Red Blood Cell
279 Distribution Width with Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection,
280 JAMA Network Open. 3 (2020) e2022058.
281 https://doi.org/10.1001/jamanetworkopen.2020.22058.

282 [14] J.L. Rapp, D. Tremblay, N. Alpert, W. Lieberman-Cribbin, J. Mascarenhas, E. Taioli, S.
283 Ghaffari, Red cell distribution width is associated with mortality in non-anemic patients
284 with COVID-19, J Med Virol. (2021) jmv.27011. https://doi.org/10.1002/jmv.27011.
285 [15] Z. Wang, Y.-W. Lin, X. Wei, F. Li, X.-L. Liao, H. Yuan, D. Huang, T. Qin, H. Geng, S. Wang,
286 Predictive Value of Prognostic Nutritional Index on COVID-19 Severity, Front. Nutr. 7
287 (2021) 582736. https://doi.org/10.3389/fnut.2020.582736.
288 [16] E. Dalbaşı, Ö.L. Akgül, Are average platelet volume, red cell distribution width and platelet
289 distribution width guiding markers for acute appendicitis treatment options?, Int J Clin
290 Pract. (2021). https://doi.org/10.1111/ijcp.14232.
291 [17] Y. Li, Y. She, L. Fu, R. Zhou, W. Xiang, L. Luo, Association Between Red Cell Distribution
292 Width and Hospital Mortality in Patients with Sepsis, J Int Med Res. 49 (2021)
293 030006052110042. https://doi.org/10.1177/03000605211004221.
294 [18] H. Go, H. Ohto, K.E. Nollet, K. Sato, H. Ichikawa, Y. Kume, Y. Kanai, H. Maeda, N.
295 Kashiwabara, K. Ogasawara, M. Sato, K. Hashimoto, M. Hosoya, Red cell distribution width
296 as a predictor for bronchopulmonary dysplasia in premature infants, Sci Rep. 11 (2021)
297 7221. https://doi.org/10.1038/s41598-021-86752-8.
298 [19] Y. Koma, A. Onishi, H. Matsuoka, N. Oda, N. Yokota, Y. Matsumoto, M. Koyama, N. Okada,
299 N. Nakashima, D. Masuya, H. Yoshimatsu, Y. Suzuki, Increased Red Blood Cell Distribution
300 Width Associates with Cancer Stage and Prognosis in Patients with Lung Cancer, PLoS ONE.
301 8 (2013) e80240. https://doi.org/10.1371/journal.pone.0080240.
302 [20] Q. Chen, R. Mao, J. Zhao, X. Bi, Z. Li, Z. Huang, Y. Zhang, J. Zhou, H. Zhao, J. Cai,
303 Nomograms incorporating preoperative RDW level for the prediction of postoperative

304 complications and survival in colorectal liver metastases after resection, Ann Palliat Med.
305 10 (2021) 4143–4158. https://doi.org/10.21037/apm-20-2418.
306 [21] T. Dingjan, A.H. Futerman, The fine-tuning of cell membrane lipid bilayers accentuates
307 their compositional complexity, BioEssays. (2021) 1–15.
308 https://doi.org/10.1002/bies.202100021.
309 [22] W.S. Harris, C. von Schacky, The Omega-3 Index: a new risk factor for death from coronary
310 heart disease?, Prev. Med. 39 (2004) 212–220.
311 https://doi.org/10.1016/j.ypmed.2004.02.030.
312 [23] H.M. Vidgren, J.J. Agren, U. Schwab, T. Rissanen, O. Hänninen, M.I. Uusitupa,
313 Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes
314 and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-
315 rich oil among healthy young men, Lipids. 32 (1997) 697–705.
316 [24] M.R. Flock, A.C. Skulas-Ray, W.S. Harris, T.D. Etherton, J.A. Fleming, P.M. Kris-Etherton,
317 Determinants of erythrocyte omega-3 fatty acid content in response to fish oil
318 supplementation: A dose–response randomized controlled trial, J. Am. Heart Assoc. 2
319 (2013) e000513. https://doi.org/10.1161/JAHA.113.000513.
320 [25] T. Terano, A. Hirai, T. Hamazaki, S. Kobayashi, T. Fujita, Y. Tamura, A. Kumagai, Effect of
321 oral administration of highly purified eicosapentaenoic acid on platelet function, blood
322 viscosity and red cell deformability in healthy human subjects, Atherosclerosis. 46 (1983)
323 321–331.
324 [26] I.J. Cartwright, A.G. Pockley, J.H. Galloway, M. Greaves, F.E. Preston, The effects of dietary
325 omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids,

326 erythrocyte deformabilit and blood viscosity in healthy volunteers, Atherosclerosis. 55
327 (1985) 267–281.
328 [27] R. Bach, U. Schmidt, F. Jung, H. Kiesewetter, B. Hennen, E. Wenzel, H. Schieffer, L. Bette, S.
329 Heyden, Effects of Fish Oil Capsules in Two Dosages on Blood Pressure, Platelet Functions,
330 Haemorheological and Clinical Chemistry Parameters in Apparently Healthy Subjects, Ann
331 Nutr Metab. 33 (1989) 359–367. https://doi.org/10.1159/000177559.
332 [28] E. Hessel, J.J. Agren, M. Paulitschke, O. Hanninen, A. Hanninen, D. Lerche, Freshwater fish
333 diet affects lipid composition, deformability and aggregation properties of erythrocytes,
334 Atherosclerosis. 82 (1990) 37–42.
335 [29] R.E. Walker, K.H. Jackson, N.L. Tintle, G.C. Shearer, A. Bernasconi, S. Masson, R. Latini, B.
336 Heydari, R.Y. Kwong, M. Flock, P.M. Kris-Etherton, A. Hedengran, R.M. Carney, A. Skulas-
337 Ray, S.S. Gidding, A. Dewell, C.D. Gardner, S.M. Grenon, B. Sarter, J.W. Newman, T.L.
338 Pedersen, M.K. Larson, W.S. Harris, Predicting the effects of supplemental EPA and DHA
339 on the omega-3 index, Am. J. Clin. Nutr. 110 (2019) 1034–1040.
340 https://doi.org/10.1093/ajcn/nqz161.
341 [30] W.S. Harris, N.L. Tintle, F. Imamura, F. Qian, A.V. Ardisson Korat, M. Marklund, L. Djoussé,
342 J.K. Bassett, P.-H. Carmichael, Y.-Y. Chen, Y. Hirakawa, L.K. Kupers, M. Lankinen, R.A.
343 Murphy, C. Samieri, M.K. Senn, P. Shi, J.K. Virtanen, I.A. Brouwer, K.-L. Chien, G.
344 Eiriksdottir, N.G. Forouhi, J.M. Geleijnse, G.G. Giles, V. Gudnason, C. Helmer, A. Hodge, R.
345 Jackson, K.-T. Khaw, M. Laakso, H. Lai, D. Laurin, J. Lindsay, R. Micha, J. Mursu, T.
346 Ninomiya, W. Post, B.M. Psaty, U. Riserus, J.G. Robinson, A.H. Shadyab, L. Snetselaar, A.
347 Sala-Vila, Y. Sun, L.M. Steffen, M.Y. Tsai, N.J. Wareham, A.C. Wood, J.H.Y. Wu, F. Hu, Q.

348 Sun, D.S. Siscovick, R.N. Lemaitre, D. Mozaffarian, F. The Fatty Acids and Outcomes
349 Research Consortium, Blood n-3 fatty acid levels and total and cause-specific mortality
350 from 17 prospective studies, Nature Commun. 12 (2021) 1–9.
351 https://doi.org/10.1038/s41467-021-22370-2.
352 [31] C. Fava, F. Cattazzo, Z.-D. Hu, G. Lippi, M. Montagnana, The role of red blood cell
353 distribution width (RDW) in cardiovascular risk assessment: useful or hype?, Ann. Transl.
354 Med. 7 (2019) 581–581. https://doi.org/10.21037/atm.2019.09.58.
355 [32] P.M. Moriarty, P.G. Steg, L.K. Gorby, A.M. Zeiher, H.D. White, T. Sourdille, M.T. Roe, M.J.
356 Louie, J.W. Jukema, R.A. Harrington, S.G. Goodman, R. Diaz, V.A. Bittner, D.L. Bhatt, M.
357 Szarek, Q.H. Li, G.G. Schwartz, Relation of Red Blood Cell Distribution Width to Risk of
358 Major Adverse Cardiovascular Events, Death, and Effect of Alirocumab After Acute
359 Coronary Syndrome, in: American Heart Association, American Heart Association,
360 Phildadelphia, PA, 2019: p. 1.
361 [33] J. Lappegård, T. Ellingsen, K. Hindberg, E. Mathiesen, I. Njølstad, T. Wilsgaard, M.-L.
362 Løchen, S. Brækkan, J.-B. Hansen, Impact of Chronic Inflammation, Assessed by hs-CRP, on
363 the Association between Red Cell Distribution Width and Arterial Cardiovascular Disease:
364 The Tromsø Study, TH Open. 02 (2018) e182–e189. https://doi.org/10.1055/s-0038-
365 1651523.
366 [34] M.A. Zimmerman, Diagnostic Implications of C-Reactive Protein, Arch Surg. 138 (2003)
367 220. https://doi.org/10.1001/archsurg.138.2.220.
368 [35] A. Villaseñor, S.W. Flatt, C. Marinac, L. Natarajan, J.P. Pierce, R.E. Patterson, Postdiagnosis
369 C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study, Cancer

370 Epidemiol Biomarkers Prev. 23 (2014) 189–199. https://doi.org/10.1158/1055-9965.EPI-
371 13-0852.
372 [36] WHO, C-reactive protein concentrations as a marker of inflammation or infection for
373 interpreting biomarkers of micronutrient status., World Health Organization, Geneva,
374 Switzerland, 2014.
375 http://apps.who.int/iris/bitstream/10665/133708/1/WHO_NMH_NHD_EPG_14.7_eng.pdf
376 ?ua=1.
377 [37] M.L. Knight, The Application of High-Sensitivity C-Reactive Protein in Clinical Practice: A
378 2015 Update, US Pharmacist. 40 (2015) 50–53.
379 [38] S. Jafarnejad, V. Boccardi, B. Hosseini, M. Taghizadeh, Z. Hamedifard, A Meta-analysis of
380 Randomized Control Trials: The Impact of Vitamin C Supplementation on Serum CRP and
381 Serum hs-CRP Concentrations, (2018).
382 https://doi.org/10.2174/1381612824666181017101810.
383 [39] T.C. Evans, D. Jehle, The red blood cell distribution width, J. Emerg. Med. 9 (1991) 71–74.
384 https://doi.org/10.1016/0736-4679(91)90592-4.
385 [40] M.D. Cappellini, I. Motta, Anemia in Clinical Practice—Definition and Classification: Does
386 Hemoglobin Change With Aging?, Sem. Hematol. 52 (2015) 261–269.
387 https://doi.org/10.1053/j.seminhematol.2015.07.006.
388 [41] T.D. Dayspring, S.A. Varvel, L. Ghaedi, D.L. Thiselton, J. Bruton, J.P. McConnell, Biomarkers
389 of cholesterol homeostasis in a clinical laboratory database sample comprising 667,718
390 patients, Journal of Clinical Lipidology. 9 (2015) 807–816.
391 https://doi.org/10.1016/j.jacl.2015.08.003.

392 [42] W.S. Harris, J.V. Pottala, R.S. Vasan, M.G. Larson, S.J. Robins, Changes in erythrocyte
393 membrane trans and marine fatty acids between 1999 and 2006 in older Americans, J.
394 Nutr. 142 (2012) 1297–1303. https://doi.org/10.3945/jn.112.158295.
395 [43] T. Nemkov, J.A. Reisz, Y. Xia, J.C. Zimring, A. D'Alessandro, Red blood cells as an organ?
396 How deep omics characterization of the most abundant cell in the human body highlights
397 other systemic metabolic functions beyond oxygen transport, Expert Review of
398 Proteomics. 15 (2018) 855–864. https://doi.org/10.1080/14789450.2018.1531710.
399 [44] R. Huisjes, A. Bogdanova, W.W. van Solinge, R.M. Schiffelers, L. Kaestner, R. van Wijk,
400 Squeezing for Life – Properties of Red Blood Cell Deformability, Front. Physiol. 9 (2018)
401 656. https://doi.org/10.3389/fphys.2018.00656.
402 [45] P.L. Else, A.J. Hulbert, Membranes as metabolic pacemakers, Clin Exp Pharmacol Physiol.
403 30 (2003) 559–564. https://doi.org/10.1046/j.1440-1681.2003.03883.x.
404 [46] T.R. Witte, A.J. Salazar, O.F. Ballester, W.E. Hardman, RBC and WBC fatty acid composition
405 following consumption of an omega 3 supplement: Lessons for future clinical trials, Lipids
406 Health Dis. 9 (2010) 31. https://doi.org/10.1186/1476-511X-9-31.
407 [47] U. Radzikowska, A.O. Rinaldi, Z. Çelebi Sözener, D. Karaguzel, M. Wojcik, K. Cypryk, M.
408 Akdis, C.A. Akdis, M. Sokolowska, The Influence of Dietary Fatty Acids on Immune
409 Responses, Nutrients. 11 (2019) 2990. https://doi.org/10.3390/nu11122990.
410 [48] T. Kamada, T. Yamashita, Y. Baba, M. Kai, S. Setoyama, Y. Chuman, S. Otsuji, Dietary
411 Sardine Oil Increases Erythrocyte Membrane Fluidity in Diabetic Patients, Diabetes. 35
412 (1986) 604–611.

413 [49] H.F. Turk, R.S. Chapkin, Membrane lipid raft organization is uniquely modified by n-3
414 polyunsaturated fatty acids, PLEFA. 88 (2013) 43–47.
415 [50] K. Gawrisch, N.V. Eldho, L.L. Holte, The structure of DHA in phospholipid membranes,
416 Lipids. 38 (2003) 445–452.
417 [51] E. Tajima, S. Abe, R. Watanabe, Y. Koyabu, F. Saito, H. Kaneda, M. Sakuma, S. Toyoda, T.
418 Inoue, Effects of purified eicosapentaenoic acid on red blood cell distribution width and
419 vascular endothelial function in patients with coronary artery disease, Vasc Fail. 1 (2017)
420 15–21. https://doi.org/10.30548/vascfail.1.1_15.
421 [52] J. Kim, H. Lee, S. Shin, Advances in the measurement of red blood cell deformability: A
422 brief review, J. Cell Biotechnol. 1 (2015) 63–79. https://doi.org/10.3233/JCB-15007.
423 [53] G.L. Salvagno, F. Sanchis-Gomar, A. Picanza, G. Lippi, Red blood cell distribution width: A
424 simple parameter with multiple clinical applications, Critical Reviews in Clinical Laboratory
425 Sciences. 52 (2015) 86–105. https://doi.org/10.3109/10408363.2014.992064.
426 [54] I. Liguori, G. Russo, F. Curcio, G. Bulli, L. Aran, D. Della-Morte, G. Gargiulo, G. Testa, F.
427 Cacciatore, D. Bonaduce, P. Abete, Oxidative stress, aging, and diseases, Clin. Intervent.
428 Aging. Volume 13 (2018) 757–772. https://doi.org/10.2147/CIA.S158513.
429 [55] M. Minetti, L. Agati, W. Malorni, The microenvironment can shift erythrocytes from a
430 friendly to a harmful behavior: Pathogenetic implications for vascular diseases,
431 Cardiovascular Research. 75 (2007) 21–28.
432 https://doi.org/10.1016/j.cardiores.2007.03.007.
433 [56] J. Heshmati, M. Morvaridzadeh, S. Maroufizadeh, A. Akbari, M. Yavari, A. Amirinejad, A.
434 Maleki-Hajiagha, M. Sepidarkish, Omega-3 fatty acids supplementation and oxidative

435 stress parameters: A systematic review and meta-analysis of clinical trials,
436 Pharmacological Research. 149 (2019) 104462.
437 https://doi.org/10.1016/j.phrs.2019.104462.
438 [57] S. Ranka, S. Lahan, T. Dalia, A. Tripathi, A. Goyal, J. Sreenivasan, S. Taduru, M. Muhammed,
439 P. Moriarty, Association Between Red Cell Distribution Width and Cardiovascular
440 Outcomes – Systematic Review and Meta-Analysis, MRAJ. 9 (2021).
441 https://doi.org/10.18103/mra.v9i7.2468.
442 [58] P.C. Calder, Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms
443 and clinical relevance, Bioch. Biophys. Acta: Mol Cell Biol Lipids. 1851 (2015) 469–484.
444 https://doi.org/10.1016/j.bbalip.2014.08.010.
445 [59] P.C. Calder, Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving
446 mediators: Concentrations in humans and the effects of age, sex, disease and increased
447 omega-3 fatty acid intake, Biochimie. 178 (2020) 105–123.
448 https://doi.org/10.1016/j.biochi.2020.08.015.
449 [60] J.D. Fontes, F. Rahman, S. Lacey, M.G. Larson, R.S. Vasan, E.J. Benjamin, W.S. Harris, S.J.
450 Robins, Red blood cell fatty acids and biomarkers of inflammation: A cross-sectional study
451 in a community-based cohort, Atherosclerosis. 240 (2015) 431–436.
452 https://doi.org/10.1016/j.atherosclerosis.2015.03.043.
453 [61] K. Li, T. Huang, J. Zheng, K. Wu, D. Li, Effect of Marine-Derived n-3 Polyunsaturated Fatty
454 Acids on C-Reactive Protein, Interleukin 6 and Tumor Necrosis Factor α: A Meta-Analysis,
455 PLoS ONE. 9 (2014) e88103. https://doi.org/10.1371/journal.pone.0088103.

456 [62] US Dept Health & Human Services, Nutrient Assessment for DRI Review, Nutient
457 Assessment for DRI Review. (2014). https://health.gov/our-work/food-nutrition/dietary-
458 reference-intakes-dris/nutrient-assessment-dri-review (accessed October 20, 2020).
459 [63] M.I. McBurney, J.B. Blumberg, R.B. Costello, M. Eggersdorfer, J.W.E. Jr, W.S. Harris, E.J.
460 Johnson, S.H. Mitmesser, R.C. Post, D. Rai, L.J. Schurgers, Beyond Nutrient Deficiency—
461 Opportunities to Improve Nutritional Status and Promote Health Modernizing DRIs and
462 Supplementation Recommendations, Nutrients. 13 (2021) 1–25.
463 https://doi.org/10.3390/nu13061844.
464 [64] P.M. Kris-Etherton, J.A. Grieger, T.D. Etherton, Dietary Reference Intakes for DHA and EPA,
465 PLEFA. 81 (2009) 99–104. https://doi.org/10.1016/j.plefa.2009.05.011.
466 [65] W.S. Harris, D. Mozaffarian, M. Lefevre, C.D. Toner, J. Colombo, S.C. Cunnane, J.M. Holden,
467 D.M. Klurfeld, M.C. Morris, J. Whelan, Towards establishing dietary reference intakes for
468 eicosapentaenoic and docosahexaenoic acids, J. Nutr. 139 (2009) 804S-819S.
469 https://doi.org/10.3945/jn.108.101329.
470 [66] A. Daak, A. Rabinowicz, K. Ghebremeskel, Omega-3 fatty acids are a potential therapy for
471 patients with sickle cell disease, Nat Rev Dis Primers. 4 (2018) 15.
472 https://doi.org/10.1038/s41572-018-0012-9.
473 [67] A.A. Daak, M.A. Lopez-Toledano, M.M. Heeney, Biochemical and therapeutic effects of
474 Omega-3 fatty acids in sickle cell disease, Complement. Therap. Med. 52 (2020) 102482.
475 https://doi.org/10.1016/j.ctim.2020.102482.
476 [68] M. Takahashi, M. Myojo, A. Watanabe, A. Kiyosue, K. Kimura, J. Ando, Y. Hirata, I. Komuro,
477 Effect of purified eicosapentaenoic acid on red cell distribution width in patients with

478 ischemic heart disease, Heart Vessels. 30 (2015) 587–594.
479 https://doi.org/10.1007/s00380-014-0526-3.
480 [69] L.T. Meital, M.T. Windsor, R.M.L. Ramirez Jewell, P. Young, K. Schulze, R. Magee, J.
481 O'Donnell, P. Jha, M. Perissiou, J. Golledge, T.G. Bailey, P. Brooks, C.D. Askew, F.D. Russell,
482 n-3 PUFAs improve erythrocyte fatty acid profile in patients with small AAA: a randomized
483 controlled trial, J. Lipid Res. 60 (2019) 1154–1163. https://doi.org/10.1194/jlr.P093013.
484 [70] E. Wolin, J. White, J.V. Pottala, M. Sasinowski, T. Dall, T.D. Dayspring, J.P. McConnell, D.M.
485 Hoefner, S.A. Varvel, D.L. Thiselton, G.R. Warnick, W.S. Harris, Comparison of
486 cardiometabolic risk biomarkers from a national clinical laboratory with the US adult
487 population, J. Clin. Lipid. 9 (2015) 817–823. https://doi.org/10.1016/j.jacl.2015.07.014.
488 [71] R.A. Murphy, P.P. Devarshi, S. Ekimura, K. Marshall, S. Hazels Mitmesser, Long-chain
489 omega-3 fatty acid serum concentrations across life stages in the USA: an analysis of
490 NHANES 2011–2012, BMJ Open. 11 (2021) e043301. https://doi.org/10.1136/bmjopen-
491 2020-043301.
492 [72] V. Veeranna, S.K. Zalawadiya, S. Panaich, K.V. Patel, L. Afonso, Comparative analysis of red
493 cell distribution width and high sensitivity C-reactive protein for coronary heart disease
494 mortality prediction in multi-ethnic population: Findings from the 1999–2004 NHANES, Int.
495 J. Cardiol. 168 (2013) 5156–5161. https://doi.org/10.1016/j.ijcard.2013.07.109.
496 [73] N. Shah, M. Pahuja, S. Pant, A. Handa, V. Agarwal, N. Patel, R. Dusaj, Red cell distribution
497 width and risk of cardiovascular mortality: Insights from National Health and Nutrition
498 Examination Survey (NHANES)-III, International Journal of Cardiology. 232 (2017) 105–110.
499 https://doi.org/10.1016/j.ijcard.2017.01.045.

500 [74] W.S. Harris, The Omega-3 Index: Clinical Utility for Therapeutic Intervention, Curr Cardiol

501 Rep. 12 (2010) 503–508. https://doi.org/10.1007/s11886-010-0141-6.

502

Table 1. Characteristics of the study population. Mean±SD.

Variable[1]	All (n=25,485)	Males (n=12,811)	Females (n=12,674)	Male vs Female Adjusted[2] p-value
O3I (%)	4.99±1.83	4.90±1.81	5.07±1.85	0.0003
RDW (%)	13.60±0.90	13.60±0.83	13.69±0.96	0.0002
MCV (fL)	92.45±4.27	92.33±4.25	92.57±4.28	0.36
Hb (g/dL)	14.40±1.21	15.14±1.03	13.65±0.88	<0.00001
CRP (mg/L)	1.23±0.77	1.21±0.75	1.25±0.78	<0.00001
BMI (kg/m^2)	27.7±5.3	28.8±4.8	25.6±5.5	<0.00001
Age (years)	54.3±14.8	54.1±14.4	54.4±15.2	0.077

[1]O3I, Omega-3 index; RDW, red blood cell distribution width; MCV, mean corpuscular volume; Hb, hemoglobin; CRP, high-sensitivity C-reactive protein; BMI, body mass index.

[2]Models were adjusted for age, BMI, and CRP (except when the model was predicting these variables).

503

504

Table 2. Characteristics of subjects by sex and omega-3 index (O3I) classification. (Mean±SD)

Variable[1]	Female[2] (n=12,674)		Male[3] (n=12,811)		Sex*O3I Interaction
	O3I ≤5.6% (n=8,475)	O3I >5.6% (n=4,199)	O3I ≤5.6% (n=9,037)	O3I >5.6% (n=3,774)	Adjusted[4] p-value
O3I (%)	3.99±0.86	7.26±1.32	3.94±0.86	7.21±1.33	0.47
RDW	13.64±0.98	13.52±0.90	13.60±0.84	13.59±0.80	0.00066
CRP (mg/L)	1.31±0.79	1.13±0.75	1.26±0.76	1.09±0.71	0.03
BMI (kg/m^2)	27.2±5.7	25.3±4.9	29.1±4.9	28.1±4.5	<0.00001
Age (years)	52.6±15.6	57.9±13.5	52.6±14.6	57.9±13.3	0.90

[1] O3I, omega-3 index; RDW, red blood cell distribution width; MCV, mean corpuscular volume; Hb, hemoglobin; CRP, high-sensitivity C-reactive protein; BMI, body mass index.

[2] All variables between O3I categories (≤5.6% vs >5.6%) for females were p<0.0001 in both adjusted and unadjusted analyses.

[3] All variables between O3I categories (≤5.6% vs >5.6%) for males were p<0.0001 in both adjusted and unadjusted analyses, except for unadjusted difference in RDW by O3I category, p=0.31.

[4] Model further adjusted for age, BMI, and CRP.

505

506

507 Figure 1. Analytical sample flow chart. RDW, red blood cell distribution width; O3I, omega-3
508 index; MCV, mean corpuscular cell volume; Hb, hemoglobin.
509
510 Figure 2. The unadjusted (A) and adjusted for age, sex, BMI and CRP (B) relationship between
511 the red blood cell distribution width (RDW) and omega-3 index (O3I) in 25,485 adults without
512 inflammation or anemia. (Predicted means and 95% confidence bands).
513
514 Figure 3. The unadjusted (A) and adjusted for age, BMI, and CRP (B) relationships between the
515 red blood distribution width (RDW) and omega-3 index (O3I) in 12,811 males (A) and 12,674
516 females (B) without inflammation or anemia. (Predicted means and 95% confidence bands).


45,715 adults
(18+ years with RDW, BMI, CRP, Age, Sex)
Bottom 0.5% O3I
(n=229)
Top 0.5% O3I
(n=229)
(n=45,257)
(44.9% Male)
Missing Hb
(n=253)
MCV >100 fL
(n=2,227)
Missing CRP
(n=1,055)
CRP >3 mg/L
(n=14,329)
(n=27,393)
Males
(n=13,492)
Females
(n=13,901)
Hb <13g/dL
(n=681)
Hb <12g/dL
(n=1,227)
Males
(n=12,811)
Females
(n=12,674)
(n=25,485)


A
Unadjusted
(n=25,485)
14.0
13.75
13.5
RDW
p<0.0001
3
6
9
O3I (%)
B
Adjusted
(n=25,485)
14.0
13.75
13.5
RDW
p<0.0001
3
6
9
O3I (%)


A
Adjusted Males
(n=12,811)
14.0
13.75
13.5
RDW
p<0.0001
3
6
9
O3I (%)
B
Adjusted Females
(n=12,674)
14.0
13.75
13.5
RDW
p<0.0001
3
6
9
O3I (%)